Core Viewpoint - Fortrea has initiated a debt tender offer to purchase up to $75,744,000 in outstanding 7.500% Senior Secured Notes due 2030, primarily to comply with indenture provisions following a divestiture [1][2]. Group 1: Tender Offer Details - The tender offer is subject to the satisfaction or waiver of specific terms outlined in the Offer to Purchase dated October 20, 2025 [2]. - The tender offer will expire at 5:00 p.m. New York City time on November 18, 2025, unless extended or terminated [3]. - Each $1,000 principal amount of the Notes validly tendered will receive $1,000 in cash, plus accrued and unpaid interest from the last interest payment date to the settlement date [3][5]. Group 2: Conditions and Procedures - The tender offer is contingent upon the satisfaction or waiver of conditions described in the Offer to Purchase [6]. - Notes must be transferred to the Tender Agent through DTC's Automated Tender Offer Program for holders wishing to tender [4]. - If the total purchase price of validly tendered Notes exceeds the Maximum Amount, proration may occur [5]. Group 3: Company Overview - Fortrea is a leading global provider of clinical development solutions, partnering with biopharmaceutical, biotechnology, and medical device companies [9]. - The company offers services across various phases of clinical trials and has extensive experience in over 20 therapeutic areas [9][10].
Fortrea Announces Tender Offer for up to $75,744,000 Aggregate Purchase Price of Outstanding Debt